B and T Lymphocyte Associated (BTLA) Kits ELISA

BTLA encodes a member of the immunoglobulin superfamily. De plus, nous expédions BTLA Anticorps (214) et BTLA Protéines (45) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
BTLA 151888 Q7Z6A9
BTLA 208154 Q7TSA3
BTLA 407756 Q6PNM1
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top BTLA Kits ELISA sur anticorps-enligne.fr

Showing 4 out of 8 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Fournisseur Livraison Prix Détails
Humain 0.11 ng/mL 0.45-30 ng/mL Typical standard curve 96 Tests Connectez-vous pour afficher 15 to 18 Days
$910.56
Détails
Souris 0.156 ng/mL 0.625-40 ng/mL   96 Tests Connectez-vous pour afficher 15 to 18 Days
$910.56
Détails
Rat 0.156 ng/mL 0.625-40 ng/mL   96 Tests Connectez-vous pour afficher 15 to 18 Days
$910.56
Détails
Humain
  96 Tests Connectez-vous pour afficher 31 to 41 Days
$728.20
Détails

Plus Kits ELISA pour BTLA partenaires d'interaction

Human B and T Lymphocyte Associated (BTLA) interaction partners

  1. Soluble BTLA is produced as a result of alternative RNA splicing. This isoform of BTLA has biological significance through changes in cellular proliferation and can predict the diagnosis of sepsis.

  2. Data suggest that both HVEM and UL144 bind a common epitope of BTLA, whether engaged in trans or in cis; these studies were conducted in cell lines representing B-lymphocytes, T-lymphocytes, and natural killer cells. (HVEM = human herpes virus entry mediator; UL144 = membrane glycoprotein UL144 of Human herpesvirus 5; BTLA = human B- and T-lymphocyte attenuator)

  3. our data suggested that the BTLA/HVEM pathway contributes to peripheral T cell suppression in hepatocellular carcinoma patients

  4. data provide the first evidence that increased BTLA predicts poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL), and blockade of BTLA with other checkpoints may potentially represent a new strategy for immunotherapy of DLBCL.

  5. The genetic variants of rs76844316 in BTLA influence the susceptibility to severe chronic hepatitis B and might play a protective role against the progression of chronic hepatitis B.

  6. The impairment of Bregs and CD19+/BTLA+ cells could play an important pathogenic role in multiple sclerosis (MS).

  7. Our data portrays BTLA as a molecule with the singular ability to provide both costimulatory and coinhibitory signals to activated CD8(+) T cells, resulting in extended survival, improved tumor control, and the development of a functional recall response.

  8. results indicate that polymorphisms rs1982809 situated in 3' UTR nearby region of BTLA gene might be considered as low-penetrating risk factor for RCC, but results have to be confirmed in further studies

  9. The percentage of circulating BTLA+CD4+ lymphocytes was significantly higher in patients with severe community acquired pneumonia.

  10. Plasma concentrations of soluble BTLA were increased early in sepsis/septic shock and correlated to severity of disease. A baseline concentration >21ng/mL was associated with a poor prognosis.

  11. this study shows that in chronic hepatitis B virus patients, a subset of inefficient interferon-gamma producing antigen-specific CD8+ T cells recruited to the liver expressed high BTLA levels

  12. this study shows that BTLA expression is likely associated with positive rather than conventional negative regulation of CD11c antigen-presenting cell stimulatory capacity

  13. rs1982809 BTLA gene polymorphism is associated with mRNA expression level and variations in the BTLA gene might be considered as potentially low-penetrating chronic lymphocytic leukemia risk factor

  14. Study showed a decreased expression of BTLA in ocular Behcet's disease suggesting that it may be involved in the development and recurrence of this disease.

  15. BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.

  16. our study confirms that CD200/BTLA deletions are recurrent genetic lesions in the biology of BCP-ALL

  17. Focal deletions of the BTLA were associated with B-cell precursor acute lymphoblastic leukemia.

  18. high BTLA expression levels in gastric cancer, identified by IHC, are an independent biomarker for the poor prognosis of patients with gastric cancer.

  19. Data indicate taht lung function and the expressions of B, T lymphocyte attenuator (BTLA) and Treg cells were lower in patients with rheumatism than those in normal controls.

  20. BTLA is a coreceptor that negatively regulates human Vgamma9Vdelta2 T-cell proliferation and has a role in immune escape for lymphoma cells

Mouse (Murine) B and T Lymphocyte Associated (BTLA) interaction partners

  1. Soluble BTLA is produced as a result of alternative RNA splicing. This isoform of BTLA has biological significance through changes in cellular proliferation and can predict the diagnosis of sepsis.

  2. these data support a role of BTLA on type I NKT cells in limiting anti-tumor immunity.

  3. these data indicate that HVEM/BTLA interactions are dispensable for the formation of de novo host antidonor isotype-specific antibodies following skin transplantation

  4. The percentage of circulating BTLA+CD4+ lymphocytes was significantly higher in mice with LPS-induced acute lung inflammation.

  5. Dendritic cells require BTLA and HVEM to actively adjust tolerizing T cell responses under steady-state conditions.

  6. these data indicate that CCR7 and BTLA cooverexpression imparts an intermediate immune phenotype in mmature dendritic cells when compared to that in CCR7- or BTLA-expressing counterparts that show a more immunocompetent or immunotolerant phenotype

  7. this study shows that miR-155 is involved in the inhibition of BTLA during CD4+ T cell activation

  8. Our findings indicate that BTLA may be involved in the control of inflammatory responses through increasing Foxp3 expression, rather than attenuating IL-17 production, in dextran sulfate sodium-induced colitis.

  9. This study uncovers a BTLA-mediated strategy used by the host that permits Listeria proliferation to enable increasing T cell responses for long-term protection.

  10. results support a model whereby BTLA on innate leukocytes is triggered by HVEM and delivers negative signals into BTLA(+) cells, thereby interfering with the protective immune response to this intestinal parasite.

  11. by coordinating expression of BTLA, RORgammat and IL-7 balance suppressive and activation stimuli to regulate gammadelta T cell homeostasis and inflammatory responses

  12. BTLA promotes the pathogenesis of virus-induced fulminant hepatitis by enhancing macrophage viability and function. Targeting BTLA may be a novel strategy for the treatment of FH.

  13. B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells.

  14. These findings support role for BTLA and/or HVEM as potential, novel diagnostic markers of innate immune response/status and as therapeutic targets of sepsis.

  15. Combined blockade of BTLA and herpesvirus entry mediator (HVEM) does not inhibit donor T cell infiltration into graft-versus-host reaction organs; instead, it decreases the functional activity of the alloreactive T cells.

  16. During increased resistance to malaria infection, BTLA regulates production of proinflammatory cytokines in a T cell-intrinsic way, while B cells intrinsically regulate the production of nonlethal Plasmodium yoelii 17NL-specific antibodies.

  17. BTLA receptor is a potential immunoregulatory target for the modulation of cytotoxic T-lymphocyte-mediated

  18. dichotomous functions of BTLA in GVHD to serve as a costimulatory ligand of HVEM and to transmit inhibitory signal as a receptor

  19. The effect of the B and T lymphocyte attenuator (BTLA; CD272) on cluster of differentiation (CD)4(+) T cell-mediated corneal immunopathology during murine herpetic stromal keratitis, was investigated.

  20. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression.

BTLA profil antigène

Antigen Summary

This gene encodes a member of the immunoglobulin superfamily. The encoded protein contains a single immunoglobulin (Ig) domain and is a receptor that relays inhibitory signals to suppress the immune response. Alternative splicing results in multiple transcript variants. Polymorphisms in this gene have been associated with an increased risk of rheumatoid arthritis.

Gene names and symbols associated with BTLA

  • B and T lymphocyte associated (BTLA) anticorps
  • B and T lymphocyte associated (Btla) anticorps
  • A630002H24 anticorps
  • BTLA anticorps
  • BTLA1 anticorps
  • CD272 anticorps

Protein level used designations for BTLA

B and T lymphocyte associated , B and T lymphocyte attenuator , B- and T-lymphocyte attenuator , B- and T-lymphocyte-associated protein

GENE ID SPECIES
460584 Pan troglodytes
487975 Canis lupus familiaris
151888 Homo sapiens
208154 Mus musculus
407756 Rattus norvegicus
Fournisseurs de qualité sélectionnés pour BTLA (BTLA) Kits ELISA
Avez-vous cherché autre chose?